Myeloproliferative Neoplasms | Specialty

When to Initiate Therapy in Myelofibrosis

September 29th 2016

Practical Risk Assessment in Myelofibrosis

September 29th 2016

Mutations, Diagnosis, and Prognosis in Myelofibrosis

September 29th 2016

Understanding Drivers of Progression in Myelofibrosis

September 29th 2016

Imetelstat Future Unclear in MDS

September 13th 2016

The future of imetelstat as a treatment for patients with myelodysplastic syndromes is uncertain following an update on 2 clinical trials.

Looking Beyond Conventional JAK Inhibition in Myelofibrosis Therapy

September 9th 2016

Currently available therapies offer meaningful clinical benefits to patients with myelofibrosis, but achieving remission will likely require new molecules targeting different pathways.

Clinicians, Researchers Continue Search for Better MDS/MPN Therapy

September 9th 2016

Diagnostic criteria and therapeutic strategies for myelodysplastic and myeloproliferative neoplasms continue to evolve as molecular and genetic studies have provided new insights into the diseases.

Pacritinib Shows Mixed Results for Advanced Myelofibrosis

August 30th 2016

Treatment with pacritinib significantly reduced spleen volume but failed to improve total symptom score compared with best available therapy for thrombocytopenic patients with high-risk myelofibrosis.

Long-Term COMFORT-I Data Confirm Ruxolitinib Survival Benefit

June 12th 2016

Final 5-year efficacy and safety data from the phase III COMFORT-I trial confirm previous findings that ruxolitinib confers a significant benefit in patients with intermediate-2 and high-risk myelofibrosis.

Dr. Ruben Mesa on COMFORT-I for Myelofibrosis

June 10th 2016

FDA Places Pacritinib on Full Clinical Hold

February 13th 2016

The FDA has placed a full clinical hold on trials exploring pacritinib, following reports of patient deaths related to intracranial hemorrhage, cardiac failure, and cardiac arrest in the phase III PERSIST-2 trial.

Dr. Harrison on 5-Year Follow-Up Data on Ruxolitinib in Patients With Myelofibrosis

December 6th 2015

Claire Harrison, MD, deputy clinical director of Cancer and Hematology, Guy's and St. Thomas' NHS, discusses 5-year follow-up data examining ruxolitinib in patients with myelofibrosis.

Ruxolitinib Continues to Impress in Long-Term Myelofibrosis Follow-Up

December 5th 2015

Ruxolitinib continues to demonstrate sustained benefits for patients with myelofribrosis in a 5-year follow-up of the phase III COMFORT-II study.

Dr. Ruben Mesa on Advancements in Polycythemia Vera

November 11th 2015

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses advancements in polycythemia vera (PV).

Individualizing Care for Patients With Polycythemia Vera

November 4th 2015

The landscape for the diagnosis and treatment of polycythemia vera (PV) is changing, and that's good news for patients and practitioners who can look to improvements ahead.

Imetelstat Promising Across Myeloproliferative Neoplasms

September 4th 2015

The telomerase inhibitor imetelstat has shown encouraging signs of clinical activity in patients with myelofibrosis and essential thrombocythemia.

Dr. Mesa on Intended Patients With Myelofibrosis for Pacritinib

August 14th 2015

Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses the intended patient population with myelofibrosis and low platelet counts for pacritinib.

Mesa Discusses Pacritinib's Potential in Myelofibrosis

June 11th 2015

Lead PERSIST-1 author Ruben A. Mesa, MD, deputy director of the Mayo Clinic Cancer Center in Scottsdale, Arizona, discussed the trial's results and pacritinib's potential to change the treatment paradigm for patients with myelofibrosis.

Dr. Mesa on Pacritinib for Myelofibrosis

June 8th 2015

Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses PERSIST-1, a phase III study which examined pacribitinib as a treatment of myelofibrosis.

Novel JAK Inhibitor Alleviates Key Myelofibrosis Symptoms

May 30th 2015

Patients with myelofibrosis achieved significantly better outcomes in spleen volume reduction and symptom control with the novel JAK2 inhibitor pacritinib compared with best available therapy.